title: Renal function and bisphosphonate safety.
authors.forename: Susan M
authors.initials: SM
authors.lastname: Ott
authors.forename: Tilman
authors.initials: T
authors.lastname: Drueke
authors.forename: Grahame
authors.initials: G
authors.lastname: Elder
authors.forename: Masafumi
authors.initials: M
authors.lastname: Fukagawa
authors.forename: Vanda
authors.initials: V
authors.lastname: Jorgetti
authors.forename: Craig B
authors.initials: CB
authors.lastname: Langman
authors.forename: Sharon
authors.initials: S
authors.lastname: Moe
authors.forename: Linda
authors.initials: L
authors.lastname: McCann
authors.forename: Angela Yee-Moon
authors.initials: AY
authors.lastname: Wang
authors.forename: Jose
authors.initials: J
authors.lastname: Weisinger
authors.forename: David
authors.initials: D
authors.lastname: Wheeler
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000009:adverse effects / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003404:Creatinine / Q000378:metabolism; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D051437:Renal Insufficiency / Q000150:complications* / Q000503:physiopathology
chemical_list: D050071:Bone Density Conservation Agents; D003404:Creatinine; D019386:Alendronate